Sera Prognostics announces publication acceptance for PRIME study

Sera Prognostics (SERA) announced that the findings of the Prematurity Risk Assessment Combined with Clinical Interventions for Improved Neonatal OutcoMEs, PRIME, study were accepted for publication in a peer-reviewed journal. The PRIME study’s abstract data was selected as a late-breaking abstract for podium presentation earlier this year at the Society for Maternal-Fetal Medicine’s, SMFM, annual meeting. “We look forward to sharing PRIME manuscript data upon publication at upcoming medical meetings and through events with our research analysts,” said Zhenya Lindgardt, President and CEO of Sera Prognostics.